Prevenar 13 Dosage/Direction for Use

Posology: For intramuscular use only.
The dose is 0.5 mL given intramuscularly, with care to avoid injection into near nerves and blood vessel. The vaccine should not be injected in the gluteal area. Do not administer Prevenar 13 intravascularly.
Infants and children 6 weeks to 17 years of age: The immunization schedules for Prevenar 13 should be based on official recommendations.
It is recommended that infants who receive a first dose of Prevenar 13 complete the vaccination course with Prevenar 13.
Infants Aged 6 weeks-6 months: 3-dose primary series: The recommended immunization series consists of 4 doses, each of 0.5 mL. The primary infant series consists of 3 doses, with the first dose usually given at 2 months of age and with an interval of at least 1 month between doses. The first dose may be given as early as 6 weeks of age. The fourth (booster) dose is recommended between 11 and 15 months of age.
2-dose primary series: Alternatively, when Prevenar 13 is given as part of a routine infant immunization program, a series consisting of 3 doses, each of 0.5 mL, may be given. The first dose may be administered from the age of 2 months, with a second dose 2 months later. The third (booster) dose is recommended between 11 and 15 months of age (see Pharmacology: Pharmacodynamics under Actions).
Prevenar 13 Schedule for Preterm Infants (<37 weeks gestation): In preterm infants, the recommended immunization series consists of 4 doses, each of 0.5 mL. The primary infant series consists of 3 doses, with the first dose given at 2 months of age and with an interval of at least 1 month between doses. The first dose may be given as early as six weeks of age. The fourth (booster) dose is recommended at approximately 12 months of age.
Unvaccinated Infants and Children ≥7 Months of Age: Infants aged 7-11 months: 2 doses, each of 0.5 mL, with an interval of at least 1 month between doses. A third dose is recommended in the second year of life.
Children aged 12-23 months: 2 doses, each of 0.5 mL, with an interval of at least 2 months between doses.
Children aged 2-5 years: One single dose of 0.5 mL.
Prevenar 13 Vaccine Schedule for Infants and Children Previously Vaccinated with pneumococcal 7-valent conjugate vaccine (Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F): Prevenar 13 contains the same 7 serotypes included in pneumococcal 7-valent conjugate vaccine, using the same carrier protein CRM₁₉₇. Infants and children who have begun immunization with pneumococcal 7-valent conjugate vaccine may switch to Prevenar 13 at any point in the schedule. (See Table 17.)


Click on icon to see table/diagram/image


Children aged 12 - 23 months: Children who have not received 2 doses of Prevenar 13 during the infant series should receive 2 doses of the vaccine (with an interval of at least 2 months between doses) to complete the immunization series for the six additional serotypes.
Children aged 2 - 5 years: One single dose.
Adults 18 Years of Age and Older: Prevenar 13 is to be administered as a single dose to adults 50 years and older including those previously vaccinated with a pneumococcal polysaccharide vaccine.
The need for re-vaccination with a subsequent dose of Prevenar 13 has not been established. For specific guidelines, please refer to local recommendation.
Special Populations: Individuals who may be at higher risk of pneumococcal infection (i.e. individuals with sickle cell disease or HIV infection). Individuals who are previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23) may receive 2 doses of Prevenar 13 with interval of 6 months between doses. Individuals who are naïve may receive 2 doses of Prevenar 13 with interval of 1 month between doses. However, there is no study for the use of Prevenar 13 in population with sickle cell disease below 6 years and above 18 years.
In individuals with a hematopoietic stem cell transplant (HSCT), the recommended immunization series consists of 4 doses of Prevenar 13, each of 0.5 mL. The primary series consists of 3 doses, with the first dose given 3 to 6 months after HSCT and with an interval of at least 1 month between doses. A booster dose is recommended 6 months after the third dose (see Pharmacology: Pharmacodynamics under Action). However, there is no study for the use of Prevenar 13 in population with HSCT below 2 years.
Method of Administration: The vaccine should be given by intramuscular injection. The preferred sites are the anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children and adults.